Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
BSE: 524689 | NSE: PDPL | Pharmaceuticals & Drugs | Small Cap
1. Is Parenteral Drugs (India) Ltd a good quality company?
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Parenteral Drugs (India) Ltd is a below average quality company.
2. Is Parenteral Drugs (India) Ltd undervalued or overvalued?
The key valuation ratios of Parenteral Drugs (India) Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
3. Is Parenteral Drugs (India) Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Parenteral Drugs (India) Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||-3.6%||-9.9%||-3.6%||-2.2%||-9.5%||-8.1%||-6%||-22.4%||-28.2%||-277.8%||-|
|Value Creation Index ⓘ||-1.3||-1.7||-1.3||-1.2||-1.7||NA||NA||NA||NA||NA||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||-15.9%||-0.4%||-5.7%||-15.4%||-64.9%||-36.9%||0.8%||-4%||-61.8%||-|
|Adj EPS ⓘ||-18.4||-32.9||-19.7||-18.1||-36||-37.4||-31.8||-49.6||-38.3||-40.8||-25.6|
|YoY Gr. Rt. %||-||NA||NA||NA||NA||NA||NA||NA||NA||NA||-|
|BVPS (₹) ⓘ||97.8||75.6||49.7||31.5||4.4||-92.2||-124.5||-174.2||-212.5||-253.3||-278.9|
|Adj Net Profit ⓘ||-47.7||-85.1||-58.7||-54||-107||-112||-94.9||-148||-114||-122||-76|
|Cash Flow from Ops. ⓘ||-4.5||-156||-21.4||-4.8||31.4||121||148||456||112||125||-|
|Debt/CF from Ops. ⓘ||-59.7||-2.3||-19.6||-95.1||17.9||5.3||4.3||1.4||5.7||5.1||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||NA||NA||NA||NA|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||-15.6||-34.2||-31.9||-40.7||-54.3||-80.3||158.8||53.3||22.6||19.6||9.6|
|Op. Profit Mgn % ⓘ||3.9||-11.8||-21.6||7.3||-31.1||-64.4||-42.8||-49.6||-46.1||-96.8||-175.8|
|Net Profit Mgn % ⓘ||-21.4||-45.4||-31.5||-30.7||-72.1||-213.6||-287.8||-445.4||-357.9||-1000.3||-898.5|
|Debt to Equity ⓘ||1||1.7||2.6||4.3||21.5||-2.3||-1.7||-1.2||-1||-0.8||-|
|Working Cap Days ⓘ||281||300||321||371||370||651||804||805||858||2,280||3,371|
|Cash Conv. Cycle ⓘ||105||125||198||258||254||482||255||-10||-32||-29||0|
No data to display
Return on Equity has declined versus last 3 years average to 9.60%
Sales growth has been subdued in last 3 years -28.25%
Sales growth is not so good in last 4 quarters at -27.39%
|TTM EPS (₹)||-25.6||-25.6|
|TTM Sales (₹ Cr.)||8.5||8.5|
|BVPS (₹.) ⓘ||-278.9||-278.8|
|Reserves (₹ Cr.) ⓘ||-861||-861|
|From the Market|
|52 Week Low / High (₹)||3.18 / 5.40|
|All Time Low / High (₹)||0.38 / 399.95|
|Market Cap (₹ Cr.)||12.1|
|Equity (₹ Cr.)||29.8|
|Face Value (₹)||10|
|Industry PE ⓘ||38|
Established in the year 1983, Parenteral Drugs has dedicated itself to the manufacturing of the best quality vital life saving drug at the lowest possible cost. Over the years, its path breaking innovation has led not only to lower costs but better quality as well because PDPL firmly believes that better quality dose not necessarily mean higher price, it can also be achieved by indigenous techniques and innovative technologies.
Commencing with production of I.V. fluids in polypropylene bottles for the first time ever, as against glass, PDPL has followed up the success in creating single use disposable eye drop It is now set to bring dialysis within the reach of the common man with its innovatively and indigenously made CAPD kits . The company went for a successful public issue in 1994. Using money merely as means to achieve an end, the company has very judiciously applied it to shape out to a reality from the blue print of the dreams of carefully identified areas of potent niche activities. A cost-effective technology at work is evident in every area of its varied production processes. In fact this is one of the rare companies which showcases the use of most modern state-of-the-art technologies co-existing in harmonious synergy with the labor intensive technologies and retained in larger societal interests.
Parenteral Drugs (India) believes in appropriate and systematic methods and observes highest standard in letter and spirit. Parenteral Drugs (India)â€™s quality standards are truly high. The company follows a stringent quality control policy, indeed takes quality control measures at every stage of the manufacturing process. The quality assurance department has a well equipped laboratory with most modern testing instrument. The quality policy has resulted in company being conferred upon the ISO 9001:2000 and WHO GMP certification by international bodies. Not just to the products at PDPL quality is pertinent to to every aspect pre-delivery service, delivery and post delivery service. It is a part of the people's attitude in every step from administration production to distribution.
PDPL is the pioneer company making 400 mg Ciprofloxacin infusion in 200 ml with 5% dextose. The I.V. fluids are packed in size ranging from 100 ml to 3 litre and dialysis solution up to 10 litres water for injection is manufactured with the help of hi-tech From-Fill-seal machine ranging from 1 ml to 10 ml.
Products manufactured by the company includes:
Solid and liquid orals
1. IV Fluids
2. Eye/ear drops